433 related articles for article (PubMed ID: 32006823)
1. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.
Oyama MA; Elliott C; Loughran KA; Kossar AP; Castillero E; Levy RJ; Ferrari G
Cardiovasc Pathol; 2020; 46():107196. PubMed ID: 32006823
[TBL] [Abstract][Full Text] [Related]
2. Pathology, protein expression and signaling in myxomatous mitral valve degeneration: comparison of dogs and humans.
Aupperle H; Disatian S
J Vet Cardiol; 2012 Mar; 14(1):59-71. PubMed ID: 22364722
[TBL] [Abstract][Full Text] [Related]
3. Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease.
Oyama MA; Levy RJ
J Vet Intern Med; 2010; 24(1):27-36. PubMed ID: 19912520
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves.
Surachetpong S; Jiranantasak T; Rungsipipat A; Orton EC
J Vet Cardiol; 2013 Sep; 15(3):171-80. PubMed ID: 23816827
[TBL] [Abstract][Full Text] [Related]
5. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data.
Hulin A; Deroanne C; Lambert C; Defraigne JO; Nusgens B; Radermecker M; Colige A
Cardiovasc Pathol; 2013; 22(4):245-50. PubMed ID: 23261354
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration.
Tan K; Markby G; Muirhead R; Blake R; Bergeron L; Fici G; Summers K; Macrae V; Corcoran B
PLoS One; 2019; 14(8):e0221126. PubMed ID: 31415646
[TBL] [Abstract][Full Text] [Related]
7. Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
Geirsson A; Singh M; Ali R; Abbas H; Li W; Sanchez JA; Hashim S; Tellides G
Circulation; 2012 Sep; 126(11 Suppl 1):S189-97. PubMed ID: 22965982
[TBL] [Abstract][Full Text] [Related]
8. Pathology of myxomatous mitral valve disease in the dog.
Fox PR
J Vet Cardiol; 2012 Mar; 14(1):103-26. PubMed ID: 22386587
[TBL] [Abstract][Full Text] [Related]
9. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease.
Disatian S; Orton EC
J Heart Valve Dis; 2009 Jan; 18(1):44-51. PubMed ID: 19301552
[TBL] [Abstract][Full Text] [Related]
10. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
[TBL] [Abstract][Full Text] [Related]
11. Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.
Driesbaugh KH; Branchetti E; Grau JB; Keeney SJ; Glass K; Oyama MA; Rioux N; Ayoub S; Sacks MS; Quackenbush J; Levy RJ; Ferrari G
J Mol Cell Cardiol; 2018 Feb; 115():94-103. PubMed ID: 29291394
[TBL] [Abstract][Full Text] [Related]
12. Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation.
Sainger R; Grau JB; Branchetti E; Poggio P; Seefried WF; Field BC; Acker MA; Gorman RC; Gorman JH; Hargrove CW; Bavaria JE; Ferrari G
J Cell Physiol; 2012 Jun; 227(6):2595-604. PubMed ID: 22105615
[TBL] [Abstract][Full Text] [Related]
13. Stress-induced remodelling of the mitral valve: a model for leaflet thickening and superimposed tissue formation in mitral valve disease.
Kruithof BPT; Paardekooper L; Hiemstra YL; Goumans MJ; Palmen M; Delgado V; Klautz RJM; Ajmone Marsan N
Cardiovasc Res; 2020 Apr; 116(5):931-943. PubMed ID: 31497851
[TBL] [Abstract][Full Text] [Related]
14. Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease.
Cremer SE; Moesgaard SG; Rasmussen CE; Zois NE; Falk T; Reimann MJ; Cirera S; Aupperle H; Oyama MA; Olsen LH
Res Vet Sci; 2015 Jun; 100():197-206. PubMed ID: 25843893
[TBL] [Abstract][Full Text] [Related]
15. Differentiating the aging of the mitral valve from human and canine myxomatous degeneration.
Connell PS; Han RI; Grande-Allen KJ
J Vet Cardiol; 2012 Mar; 14(1):31-45. PubMed ID: 22364720
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease.
Yang VK; Tai AK; Huh TP; Meola DM; Juhr CM; Robinson NA; Hoffman AM
PLoS One; 2018; 13(1):e0188617. PubMed ID: 29315310
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-induced PI3K/AKT/mTOR pathway controls myofibroblast differentiation and secretory phenotype of valvular interstitial cells through the modulation of cellular senescence in a naturally occurring in vitro canine model of myxomatous mitral valve disease.
Tang Q; Markby GR; MacNair AJ; Tang K; Tkacz M; Parys M; Phadwal K; MacRae VE; Corcoran BM
Cell Prolif; 2023 Jun; 56(6):e13435. PubMed ID: 36869852
[TBL] [Abstract][Full Text] [Related]
18. Signaling pathways in mitral valve degeneration.
Orton EC; Lacerda CM; MacLea HB
J Vet Cardiol; 2012 Mar; 14(1):7-17. PubMed ID: 22364692
[TBL] [Abstract][Full Text] [Related]
19. Deletion of Fstl1 (Follistatin-Like 1) From the Endocardial/Endothelial Lineage Causes Mitral Valve Disease.
Prakash S; Borreguero LJJ; Sylva M; Flores Ruiz L; Rezai F; Gunst QD; de la Pompa JL; Ruijter JM; van den Hoff MJB
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):e116-e130. PubMed ID: 28705792
[TBL] [Abstract][Full Text] [Related]
20. Gene network and canonical pathway analysis in canine myxomatous mitral valve disease: a microarray study.
Lu CC; Liu MM; Culshaw G; Clinton M; Argyle DJ; Corcoran BM
Vet J; 2015 Apr; 204(1):23-31. PubMed ID: 25841900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
